BioSpace News Archive

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Northcott has joined the company in a newly created position of Chief Commercial Officer (CCO).

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that representatives of its apparel brand SpydaSilkTM attended Vietnam’s premiere textile and garment industry exhibition, SaigonTex.

Lucira Health, Inc. (“Lucira Health” or “Lucira”) (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of innovative infectious disease tests today announced that on July 27, 2022, the Board of Directors of Lucira granted inducement awards consisting of 1,051,405 restricted stock units (“RSUs”) under Lucira’s 2022 Inducement Plan.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), today announced that the first patient has been dosed in the Phase 2 “Durasert® and Vorolanib in Ophthalmology 2" (DAVIO 2) clinical trial of EYP-1901, an investigational sustained delivery anti-vascular endothelial growth factor (anti-VEGF) treatment for wet age-related macular degeneration (wet AMD).

Covaris, LLC (“Covaris” or “the Company”), a manufacturer of advanced tools enabling life science innovations, announced today that it has appointed Annemarie Watson as Chief Executive Officer, effective immediately.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2022 and provide a business update on August 8, 2022.

Transit Scientific reports multiple successful peripheral vascular procedures with the XO Cross Catheter Platform utilizing pedal retrograde access.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced up to a US$45 million investment from Petrichor Healthcare Capital Management (“Petrichor”).

Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced that Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis, will be participating on the Systems Biology of Alzheimer’s Disease Panel at the Alzheimer’s Association International Conference (AAIC).

BridGene Biosciences, Inc. today announced that David Sperandio , Ph.D., a medicinal chemist with more than 20 years’ experience, has joined the company as the Head of Chemistry.